Andrew Pucker, OD, PhD, FAAO, FSLS, FBCLA, discussed how oculomics research presented at AAOpt 2026 could eventually support point-of-care diagnosis and referral decisions.
|Articles|November 13, 2014
Vision therapy: Questions to ask
Glen Steele, OD, FAAO, recently gave a presentation at the American Academy of Optometry's Academy 2014 in Denver, CO, on the questions to ask and tests to conduct when considering vision therapy for a patient.
Advertisement
Glen Steele, OD, FAAO, recently gave a presentation at the American Academy of Optometry's Academy 2014 in Denver, CO, on the questions to ask and tests to conduct when considering
Want more from Academy 2014?
Advertisement
Related to this article
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for optometrists managing near vision loss.
Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin (IL)-6 receptor inhibitor approved in the indication.
Susan Gromacki, OD, MS, FAAO, FSLS, details one of her AAOpt 2026 sessions, titled "Advances in Contact Lens Care for the New Contact Lens Technologies."
Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.
Presenters from AAOpt26's research symposium share their findings, applications for optometric practice, and goals for future study.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
2
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
3
Missed AAOpt 2026? Here are the highlights by specialty
4
FDA approves subcutaneous Enspryng for TED
5